5. Bibliography
1. Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol. 1997;100(2):182-184. doi:10.1016/s0091-6749(97)70222-7
2. Lafuente A, Javaloyes G, Berroa F, et al. Early skin testing is effective for diagnosis of hypersensitivity reactions occurring during anesthesia. Allergy. 2013;68(6):820-822. doi:10.1111/all.12154
3. Fisher MM. Intradermal testing after severe histamine reactions to intravenous drugs used in anaesthesia. Anaesth Intensive Care. 1976;4(2):97-104. doi:10.1177/0310057X7600400202
4. Aalto-Korte K, Mäkinen-Kiljunen S. False negative SPT after anaphylaxis. Allergy. 2001;56(5):461-462. doi:10.1034/j.1398-9995.2001.056005461.x
5. Culp JA, Palis RI, Castells MC, Lucas SR, Borish L. Perioperative anaphylaxis in a 44-year-old man. Allergy Asthma Proc. 2007;28(5):602-605. doi:10.2500/aap2007.28.3047
6. Soetens F, Rose M, Fisher M. Timing of skin testing after a suspected anaphylactic reaction during anaesthesia. Acta Anaesthesiol Scand. 2012;56(8):1042-1046. doi:10.1111/j.1399-6576.2011.02643.x
7. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437. doi:10.1111/all.12350
8. Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442-453.
9. Li PH, Chiang V, Yeung HH, Au EY. Caution Against Temporary Tolerance and Negative Skin Testing During the Anergic Period Following Systemic Reactions. J Investig Allergol Clin Immunol. 2022;32(2):157-158. doi:10.18176/jiaci.0724
10. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-1393. doi:10.1016/j.jaci.2022.08.028
11. Mohamed OE, Baretto RL, Walker I, et al. Empty mast cell syndrome: fallacy or fact? J Clin Pathol. 2020;73(5):250-256. doi:10.1136/jclinpath-2019-206157
12. Xiang Z, Block M, Löfman C, Nilsson G. IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography. J Allergy Clin Immunol. 2001;108(1):116-121. doi:10.1067/mai.2001.116124
13. Fukuishi N, Murakami S, Ohno A, et al. Does β-hexosaminidase function only as a degranulation indicator in mast cells? The primary role of β-hexosaminidase in mast cell granules. J Immunol. 2014;193(4):1886-1894. doi:10.4049/jimmunol.1302520
14. Balseiro-Gomez S, Flores JA, Acosta J, Ramirez-Ponce MP, Ales E. Transient fusion ensures granule replenishment to enable repeated release after IgE-mediated mast cell degranulation. J Cell Sci. 2016;129(21):3989-4000. doi:10.1242/jcs.194340
15. Hammel I, Lagunoff D, Krüger PG. Recovery of rat mast cells after secretion: a morphometric study. Exp Cell Res. 1989;184(2):518-523. doi:10.1016/0014-4827(89)90349-2
16. Seagrave J, Oliver JM. Antigen-dependent transition of IgE to a detergent-insoluble form is associated with reduced IgE receptor-dependent secretion from RBL-2H3 mast cells. J Cell Physiol. 1990;144(1):128-136. doi:10.1002/jcp.1041440117
17. Nagata Y, Suzuki R. FcεRI: A Master Regulator of Mast Cell Functions. Cells. 2022;11(4):622. doi:10.3390/cells11040622
18. Adnan A, Acharya S, Alenazy LA, et al. Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1. J Immunol. 2023;210(6):709-720. doi:10.4049/jimmunol.2100485
19. Huber M. Activation/Inhibition of mast cells by supra-optimal antigen concentrations. Cell Commun Signal. 2013;11(1):7. doi:10.1186/1478-811X-11-7
20. Gimborn K, Lessmann E, Kuppig S, Krystal G, Huber M. SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels. J Immunol. 2005;174(1):507-516. doi:10.4049/jimmunol.174.1.507
21. Hernandez-Hansen V, Smith AJ, Surviladze Z, et al. Dysregulated FcepsilonRI signaling and altered Fyn and SHIP activities in Lyn-deficient mast cells. J Immunol. 2004;173(1):100-112. doi:10.4049/jimmunol.173.1.100
22. Leitges M, Gimborn K, Elis W, et al. Protein kinase C-delta is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol. 2002;22(12):3970-3980. doi:10.1128/MCB.22.12.3970-3980.2002
23. Zhang J, Chiang YJ, Hodes RJ, Siraganian RP. Inactivation of c-Cbl or Cbl-b differentially affects signaling from the high affinity IgE receptor. J Immunol. 2004;173(3):1811-1818. doi:10.4049/jimmunol.173.3.1811
24. Haddon DJ, Antignano F, Hughes MR, et al. SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo. J Immunol. 2009;183(1):228-236. doi:10.4049/jimmunol.0900427
25. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95(2):370-376. doi:10.1016/j.ygyno.2004.08.002
26. Kato T, Kimata M, Tsuji T, et al. Role of protein kinase A in the inhibition of human mast cell histamine release by β-adrenergic receptor agonists. Allergology International. 2002;51(3):197-203. doi:10.1046/j.1440-1592.2002.00265.x
27. Grönneberg R, Raud J. Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin. Allergy. 1996;51(10):685-692.
28. Cohan VL, Undem BJ, Fox CC, Adkinson NF, Lichtenstein LM, Schleimer RP. Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am Rev Respir Dis. 1989;140(4):951-954. doi:10.1164/ajrccm/140.4.951
29. Schleimer RP, Schulman ES, MacGlashan DW, et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest. 1983;71(6):1830-1835. doi:10.1172/jci110938